Uncategorized

Celcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A

Published

3 hours ago

on

Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version